

Current and Emerging Concepts for Preoperative Evaluation

Adam C. Schaffer, MD, MPH
Associate Physician, Hospital Medicine Unit
Department of Medicine
Brigham and Women's Hospital
Assistant Professor or Medicine, Part-Time
Harvard Medical School

CONTINUING MEDICAL EDUCATION DEPARTMENT OF MEDICINE



Disclosures

• I have no financial disclosures

Learning Objectives

- Review the key perioperative guidelines
- Go through the major risk assessment tools
- Consider issues related to perioperative medication management
- Detail some perioperative considerations in specific patient populations



Clinical Case

- 76-year-old male with severe COPD, on 3 L of home O₂ and chronic prednisone 7.5 mg daily, DMII on metformin, dyspnea with minimal exertion.
- No history of MI or CHF. His EKG is essentially normal.
- He has metastatic colon cancer, with a single metastasis to the brain causing left arm weakness
- You are seeing him in consultation prior to neurosurgery scheduled 48 h from now to resect the metastasis
- He underwent successful resection of a colon mass 3 years ago



Introduction

- The role of the clinician performing preoperative evaluation is not to provide medical "clearance" prior to surgery
- Instead, the clinician should:
 - Assess the patient's cardiac and other risks going into the procedure
 - Decide whether additional preoperative testing, such as a cardiac stress test, is needed
 - When indicated, recommend measures to reduce perioperative risk, such as beta blockers and statins
 - Assist the surgeon in deciding whether the benefits of the surgery outweigh the risks



5

The Current Periop Guidelines were Published in 2014







2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Lee A. Fleisher, Kirsten E. Fleischmann, Andrew D. Auerbach, Susan A. Barnason, Joshua A. Beckman, Biykem Bozkurt, Victor G. Davila-Roman, Marie D. Gerhard-Herman, Thomas A. Holly, Garvan C. Kane, Joseph E. Marine, M. Timothy Nelson, Crystal C. Spencer, Annemarie Thompson, Henry H. Ting, Barry F. Uretsky and Duminda N. Wijeysundera

Circulation. published online August 1, 2014;
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539







Risk Assessment in the 2014 Guidelines

- For risk assessment, the 2014 guidelines recommend estimating the preoperative risk of a major adverse cardiac event (MACE), which here is defined as death or MI
- The risk of MACE is a function of both the risk associated with the procedure and the risk associated with the patient
- If there is a low risk of MACE, which is defined as < 1%, then one goes to surgery



9


Risk Assessment in the 2014 Guidelines

The guidelines suggest three ways to determine if the MACE risk is $\geq 1\%$:

- 1. ACS NSQIP Surgical Risk Calculator (http://www.riskcalculator.facs.org/)
- Perioperative Cardiac Risk Calculator (http://www.surgicalriskcalculator.com/miorcardiacarrest)
- 3. RCRI score (though one of the two options above is preferred because they outperform the RCRI score)




ACS NSQIP Surgical Risk Calculator



Surgeons. Aug 2013;217(2):336-346.e331.

ACS NSQIP Surgical Risk Calculator



衄

Source: Cohen ME, Ko CY, Bilimoria KY, et al. Optimizing ACS NSQIP modeling for evaluation of surgical quality and risk: Journal of the American College of Surgeons. Aug 2013;217(2):336-346.e331.

12

Perioperative Cardiac Risk Calculator

Estimate risk of perioperative myocardial infarction or cardiac arrest.

Age Creatinine <1.5 mg/dL / 133 µmol/L **ASA Class** ASA 1 ASA 1 = Normal healthy patientASA 2 = Patients with mild systemic disease

ASA 3 = Patients with severe systemic disease ASA 4 = Patients with severe systemic disease

that is a constant threat to life

ASA 5 = Moribund patients who are not expected

to survive without the operation

Preoperative Function Totally Independent

Procedure Anorectal

Submit



Source: Gupta PK, Gupta H, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation. Jul 26 2011;124(4):381-387.

13

Revised Cardiac Risk Index


Risk Factor	Definition
1. High-risk type of surgery	Intraperitoneal, intrathoracic, or suprainguinal vascular procedures
2. Ischemic heart disease	History of MI, positive stress test, current cardiac CP, nitrate usage, ECG with pathologic Q waves
3. History of congestive heart failure	History of CHF, pulmonary edema, or PND; rales or S3 on exam; chest x-ray with pulmonary edema
4. History of cerebrovascular disease	History of transient ischemic attack or stroke
5. Insulin therapy for diabetes	
6. Preoperative serum creatinine > 2.0 mg/dL	

• "A patient with 0 or 1 [RCRI] predictor(s) of risk would have a low risk of MACE. Patients with ≥ 2 predictors of risk would have elevated risk."



Sources: Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. Sep 7 1999;100(10):1043-1049. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management... Circulation. 2014 Dec 9;130(24):e278-333.

ACC/AHA 2014 Periop Guidelines




- Under the guidelines, if your risk of MACE is low (< 1%), then you go to surgery
- If you risk is elevated (≥ 1%), then you consider the patient's functional capacity



15

ACC/AHA 2014 Periop Guidelines



If your functional capacity is ≥ 4 METs, then you proceed to surgery



Duke Activity Status Index

- 1. Take care of yourself by eating, dressing, bathing, toileting (2.75)
- 2. Walk indoors, such as around your house (1.75)
- 3. Walk a block or 2 on level ground (2.75)
- 4. Climb a flight of stairs or walk up hill (5.50)
- 5. Run a short distance (8.00)
- 6. Do light housework, such as dusting or washing dishes (2.70)
- 7. Do moderate housework, such as vacuuming, sweeping, or carrying groceries (3.50)
- 8. Do heavy housework, such as scrubbing floors or moving heavy furniture (8.00)
- 9. Do yard work, such as raking, weeding, or pushing a power mower (4.50)
- 10. Have sexual relations (5.25)
- 11. Moderate recreation, such as golf, bowling, dance, doubles tennis (6.00)
- 12. Strenuous sports, such as swimming, singles tennis, football, basketball (7.50)



Source: Hlatky MA, et al. A brief self-administered questionnaire ... (the Duke Activity Status Index). The American Journal of Cardiology. 1989;64(10):651-654.


17

Duke Activity Status Index

- Methods to use the DASI:
 - Online METs calculators based on DASI
 - E.g.: https://www.mdcalc.com/calc/3910/duke-activity-status-index-dasi
 - DASI scores > 34 are associated with a reduced risk of 30-d death or MI



ACC/AHA 2014 Periop Guidelines



If your functional capacity is
 4 METs, then consider
 pharmacologic stress testing,
 if it will change management




19

Preop Stress Tests Use is Declining

801,396 elective total hip or total knee arthroplasty patients

B Type of preoperative stress test performed 2004-2017



	RCRI, No./total No. (%)					
Year	0					
2004	1636/3659 (44.7)					
2005	2393/5268 (45.4)					
2006	2323/4966 (46.8)					
2007	2644/5414 (48.8)					
2008	2763/5670 (48.7)					
2009	2992/6003 (49.8)					
2010	2865/5710 (50.2)					
2011	3506/6980 (50.2)					
2012	3315/6514 (50.9)					
2013	2674/5414 (49.4)					
2014	2843/5606 (50.7)					
2015	2013/4117 (48.9)					
2016	1790/3552 (50.4)					
2017	1594/3032 (52.6)					
Total	35 351/71 905 (49.2)					



Source: Rubin DS et al. frequency and outcomes of preoperative stress testing in total hip and knee arthroplasty from 2004 to 2017. JAMA Cardiol. 2021 Jan 1;6(1):13-20.



Preoperative ECGs in the 2014 ACC/AHA Guidelines

- Class IIa: Preop resting 12-lead ECG is reasonable for patients with known coronary heart disease, significant arrhythmia, peripheral arterial disease, cerebrovascular disease, or other significant structural heart disease, except for those undergoing lowrisk surgery
- Class IIb: Preop resting 12-lead ECG may be considered for asymptomatic patients without known coronary heart disease, except for those undergoing low-risk surgery
- Class III: Routine preop resting 12-lead ECG is not useful for asymptomatic patients undergoing low-risk surgical procedures



Perioperative Troponin Measurements in High-Risk Patients without Symptoms


- 2014 ACC/AHA Guidelines: "The usefulness of postoperative screening with troponin levels in patients at high risk for perioperative MI but without signs or symptoms suggestive of myocardial ischemia or MI is uncertain"
- 2018 European Society of Anaesthesiology Guidelines: "We suggest considering assessment of cardiac troponins in high-risk patients, both before and 48 to 72 h after major surgery"



Source: Smilowitz NR, Berger JS. Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review. JAMA. 2020 Jul 21;324(3):279-290.

23

Perioperative Troponin Measurements in High-Risk Patients without Symptoms: 2022 ESC Guidelines



Source: Halvorsen S, et al. ESC Scientific Document Group. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022 Oct 14;43(39):3826-3924.

鹼

Perioperative Troponin Measurements in High-Risk Patients without Symptoms

- Key question: how will the troponin measurement change your management?
 - · Prompt assessment of etiology
 - · Inform decision to add an ASA or statin
 - · Alter intensity of monitoring
 - May also change management in the longer term
- A challenge: determining if a postoperative troponin elevation is a change from baseline



Source: Smilowitz NR, Berger JS. Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review. JAMA. 2020 Jul 21-22/(3)-279-290

25

Perioperative Beta Blockers: 2014 Guideline Recommendations

- Perioperative beta blockade appears to be of benefit in selected patients who are at elevated risk of perioperative cardiac events
- Per the ACC/AHA 2014 Periop Guidelines, there is one class I indication for perioperative beta-blocker use:
 - "Beta blockers should be continued in patients undergoing surgery who have been on beta blockers chronically"
- What to do in patients who are not already on beta blockers is unsettled



Perioperative Beta Blockers: The POISE Trial

- The PeriOperative ISchemic Evaluation (POISE) Trial enrolled 8351 patients undergoing noncardiac surgery with at least one cardiac risk factor
- Patients were randomized to either placebo or controlled-release metoprolol (CR metoprolol) 100 mg orally 2 – 4 h before surgery, a postop dose of CR metoprolol based on heart rate and BP, and then 200 mg of CR metoprolol orally daily for the next 30 d
- The beta blocker arm had a lower rate of the primary outcome (30-day cardiac events): 5.8% in the beta blocker arm versus 6.9% in the placebo arm (P=0.04)
- However, the total mortality was higher in the CR metoprolol group (3.1%) than in the placebo group (2.3%) (P=0.03)
- The general view of this trial is that the dose of periop beta blockers given was too large, and so led to the increased stroke rate



Source: Poise Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial).... Lancet. May 31 2008;371(9627):1839-1847. 27

Perioperative Beta Blockers: The POISE Trial

- The PeriOperative ISchemic Evaluation (POISE) Trial enrolled 8351 patients undergoing noncardiac surgery with at least one cardiac risk factor
- Patients were randomized to either placebo or controlled-release metoprolol (CR metoprolol 100 mg orally 2 = 4 h before surgery a poston dose of CR metoprolol based on Giving high doses of beta blockers without dose ilv for the next 30 d titration to beta blocker naïve patients right before
- The beta I events): 5 surgery increases mortality cardiac =0.04)
- However, the total mortality was higher in the CK metoprologgroup (3.1%) than in the placebo group (2.3%) (P=0.03)
- The general view of this trial is that the dose of periop beta blockers given was too large, and so led to the increased stroke rate



Perioperative Beta Blockers: Retrospective Data

- A large retrospective cohort study examining the benefits of periop beta blockers based on the cardiac risk of the patient
- Patients undergoing noncardiac surgery (mainly orthopedic and abdominal procedures) were included
- Patients receiving prophylactic periop beta blockers were compared with patients not receiving beta blockers
- This study is debated:
 - On the one hand, it was guite large (n=663,635)
 - On the other hand, it was retrospective, and based on the use of an administrative database. No charts were reviewed. Beta blockers started on hospital day 1 or 2 were considered prophylactic




Source: Lindenauer PK, et al. Perioperative beta-blocker therapy New England Journal of Medicine. Jul 28 2005;353(4):349-361.

29

Perioperative Beta Blockers: Retrospective Data

- Patients without cardiac risk factors who got periop beta blockers seemed to be harmed by them
- Patients with an RCRI of at least 2, and certainly with an RCRI of 3, appeared to benefit from beta blockers






Source: Lindenauer PK, et al. Perioperative beta-blocker therapy New England Journal of Medicine. Jul 28 2005;353(4):349-361.

Perioperative Beta Blockers: Retrospective Data

- Patients without cardiac risk factors who got periop beta blockers seemed to be harmed by them
- Patients with an RCRI of at least 2, and certainly with an RCRI of 3, appeared to benefit from beta blockers.

As the RCRI score goes up, the benefit from beta blockers increases. Beta blockers conferred a mortality benefit with an RCRI score ≥ 3.





Source: Lindenauer PK, et al. Perioperative beta-blocker therapy New England Journal of Medicine. Jul 28 2005;353(4):349-361.

31

Perioperative Beta Blockers: 2014 ACC/AHA Recommendations

- The 2014 AHA guidelines are offer mainly IIb recommendations about when to start periop beta blockers in those who are not on them
- In patients with an RCRI score of 3 or more, it may be reasonable to begin beta blockers prior to surgery (class IIb recommendation)
- "In patients with a compelling long-term indication for beta-blocker therapy but no other RCRI risk factors, initiating beta blockers in the perioperative setting as an approach to reduce perioperative risk is of uncertain benefit"
- Beta-blocker therapy should not be started on the day of surgery (class III recommendation)



Perioperative Statins

- The DECREASE-III trial enrolled 497 patients, age > 40, at elevated cardiac risk, scheduled to undergo noncardiac vascular surgery
- All patients had to be statin naïve
- All patients were on beta blockers
 - · Patients who were already taking a beta blocker were continued on this beta blocker
 - Patients who were not on a beta blocker were started on one, and their dose was titrated based on their HR
- Patients were randomized to fluvastatin 80 mg daily or a placebo. This statin was started on average 37 days prior to surgery and continued for at least 30 days after surgery





Source: Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. NEJM. Sep 3 2009;361(10):980-989.

33

Perioperative Statins

Perioperative Myocardial Ischemia: 10.8% in the statin arm vs. 19.0% in the placebo arm (P = 0.01) Perioperative death from CV cause or MI: 4.8% in the statin arm vs. 10.1% in the placebo arm (P = 0.03)





Source: Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. NEJM. Sep 3 2009;361(10):980-989.

Perioperative Statins: Meta-Analysis

	Stati	Statin No statin		atin	Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Poldermans	12	93	148	387	11.6%	0.24 [0.13, 0.45]	2003	-
Durazzo	7	44	10	46	7.0%	0.68 [0.23, 1.98]	2004	
Abbruzzese	2	88	3	84	3.3%	0.63 [0.10, 3.86]	2004	
Ward	2	72	9	374	4.2%	1.16 [0.25, 5.48]	2005	
Kennedy	7	1480	21	1803	9.0%	0.40 [0.17, 0.95]	2005	
O'Neil-Callahan	6	526	5	637	6.1%	1.46 [0.44, 4.81]	2005	
McGirt	2	657	19	909	4.6%	0.14 [0.03, 0.62]	2005	
Leurs	11	731	134	5161	11.9%	0.57 [0.31, 1.07]	2006	-
Gröschel	0	53	2	127	1.3%	0.47 [0.02, 9.94]	2006	-
Schouten 2	1	28	8	49	2.5%	0.19 [0.02, 1.61]	2006	
Kor	9	85	4	62	5.9%	1.72 [0.50, 5.85]	2008	
Schanzer	17	636	21	768	11.5%	0.98 [0.51, 1.87]	2008	-
Schouten 1	6	250	12	247	7.7%	0.48 [0.18, 1.30]	2009	
Puato	0	39	0	19		Not estimable	2010	
McNally	0	181	11	220	1.5%	0.05 [0.00, 0.86]	2010	
Moulakakis	0	58	0	69		Not estimable	2010	
Le Manach	17	880	27	794	11.9%	0.56 [0.30, 1.03]	2011	-
Verzini	0	465	0	618		Not estimable	2011	
Neilipovitz	0	22	0	8		Not estimable	2012	
Total (95% CI)		6388		12382	100.0%	0.54 [0.38, 0.78]		•
Total events	99		434					
Heterogeneity: Tau ² =	0.19: Ch	$i^2 = 24$	51. df = 1	4 (P = 0.	04); $I^2 = 4$;	3%		
Test for overall effect:								0.01 0.1 1 10 100 Favours statin Favours no statin



Source: Antoniou GA, Hajibandeh S, Vallabhaneni SR, Brennan JA, Torella F. Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery. *Journal of Vascular Surgery*. Feb 2015;61(2):519-532 e511

35

Perioperative Statins: Meta-Analysis

	Stati	in	No sta	atin	Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI
Poldermans	12	93	148	387	11.6%	0.24 [0.13, 0.45]	2003	
Durazzo	7	44	10	46	7.0%	0.68 [0.23, 1.98]	2004	
Abbruzzese	2	88	3	84	3.3%	0.63 [0.10, 3.86]	2004	
Ward	2	72	9	374	4.2%	1.16 [0.25, 5.48]	2005	
Kennedy	7	1480	21	1803	9 N%	0.40 (0.17. 0.95)	2005	
In this m	eta-	·an	aivs	IS, K	perio	op statins	SIg	nificantly
						•		· · · · · · · · · · · · · · · · · · ·
reduced	all-d	าลม	SP r	$n \cap r$	talit	:y (odds ra	tio	0.54
reduced	un (Juu	JC 1		tunt	y (odds id	tio	0.54,
OFO/ CLO	20	0 7	701					
95% CI 0	.38-	·U. /	٥).					
ocnoulen i		200	14	471	1.1.70	0.40 (0.10, 1.00)	2000	
Puato	0	39	0	19		Not estimable	2010	
McNally	0	181	11	220	1.5%	0.05 [0.00, 0.86]	2010	-
Moulakakis	0	58	0	69		Not estimable	2010	
Le Manach	17	880	27	794	11.9%	0.56 [0.30, 1.03]	2011	-
Verzini	0	465	0	618		Not estimable	2011	
Neilipovitz	0	22	0	8		Not estimable	2012	
Total (95% CI)		6388		12382	100.0%	0.54 [0.38, 0.78]		•
Total events	99		434					
Heterogeneity: Tau ² =	0.19: Ch	$i^2 = 24$	51. df = 1	4 (P = 0.	04): $I^2 = 4$	3%		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Test for overall effect:								0.01 0.1 1 10 100
. Cot ioi oralan enect.	2 - 3.20	, -0.0						Favours statin Favours no statin



Source: Antoniou GA, Hajibandeh S, Vallabhaneni SR, Brennan JA, Torella F. Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery. *Journal of Vascular Surgery*. Feb 2015;61(2):519-532 e511

Perioperative Statins: 2014 ACC/AHA Recommendations

- Statins should be continued in patients currently taking statins and scheduled for noncardiac surgery (class I)
- Perioperative initiation of statins is reasonable in patients undergoing vascular surgery (class IIa)
- Perioperative initiation of statins may be considered in patients with clinical indications according to GDMT who are undergoing elevatedrisk procedures (class IIb)



37

Perioperative Aspirin

- The POISE 2 Trial was an that looked at the effect of perioperative ASA
- The trial enrolled 10,010 patients undergoing noncardiac surgery who were at risk for vascular complications
- Patient within the coronary stent critical periods were excluded
- The primary endpoint was death or nonfatal MI at 30 days
- The patients were stratified by whether they were already taking ASA (continuation group) or not (initiation group)



Perioperative Aspirin

- There was no benefit to ASA in the primary outcome or any of the secondary outcomes
- The negative results were the same for the continuation group and the initiation group
- Taking ASA was associated with an increased risk of major bleeding



Source: Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. NEJM. Apr 17 2014;370(16):1494-1503.

30

Perioperative Aspirin




Figure 1. Kaplan–Meier Estimates of the Primary Composite Outcome of Death or Nonfatal Myocardial Infarction at 30 Days.

The inset shows the same data on an enlarged y axis.





Figure 2. Subgroup Analyses of the Primary Outcome

The primary composite outcome was death or nonfatal myocardial infarction at 30 days. The area of each square is proportional to the size of the corresponding subgroup. The Revised Cardiac Risk Index ranges from 0 to 6, with higher scores indicating greater risk.

Source: Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. NEJM. Apr 17 2014;370(16):1494-1503.



Should We Hold ACEI/ARB Periop?

JAMA | Original Investigation

Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery The Stop-or-Not Randomized Clinical Trial

JAMA. 2024;332(12):970-978. doi:10.1001/jama.2024.17123 Published online August 30, 2024.



Should We Hold ACEI/ARB Periop?

- Prospective RCT of 2222 patients in France
- Patients were on a renin-angiotensin system inhibitors (RASIs) (ACEI or ARB) for ≥ 3 months
- Patients were randomized 1:1 to the continuation group (continued ACEI/ARB to the day of surgery) or discontinuation group (held ACEI/ARB for 48 h before surgery)




Source: Legrand M, et al; Stop-or-Not Trial Group. Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024 Sep 24;332(12):970-978.

43

Should We Hold ACEI/ARB Periop?








Source: Legrand M, et al; Stop-or-Not Trial Group. Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024 Sep 24;332(12):970-978.

Should We Hold ACEI/ARB Periop?

Figure 2. Primary Outcome for All Patients and by Individual Patient Subgroups

	Discontinued use of RASIs		Continued use of RASIs		
	No. of events	No. of patients	No. of events	No. of patients	Risk ratio (95% CI)
Primary outcome					
All patients	245	1115	247	1107	1.02 (0.87-1.19)
Patient subgroups					
Age group, y					
≤80	225	1026	230	1037	1.01 (0.86-1.19)
>80	20	89	17	70	1.08 (0.61-1.90)
History of chronic kidney disease					
No	212	1013	208	1011	0.98 (0.83-1.17)
Yes	33	102	39	96	1.26 (0.87-1.82)
History of heart failure					
No	230	1043	231	1038	1.01 (0.86-1.19)
Yes	15	72	16	69	1.11 (0.60-2.07)





Source: Legrand M, et al; Stop-or-Not Trial Group. Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024 Sep 24;332(12):970-978.

45

Perioperative Considerations for GLP-1 Agonists

Guidance from the American Society of Anesthesiologists:

- For patients who take GLP-1 agonists daily, consider holding the medication on the day of surgery
- For patients who take GLP-1 agonists weekly, consider holding the medication a week prior to surgery
- If the patient has GI symptoms such as serious bloating or N/V, consider delaying the procedure
- If the patient has no GI symptoms but did not hold the GLP-1 agonist, then use "full stomach" precautions



Perioperative Considerations for GLP-1 Agonists

Guidance from the American Society of Anesthesiologists:

- · For patients who take GLP-1 agonists daily, consider holding the medication on the day of surgery
- · For patients who take GLP-1 agonists weekly, consider holding the medication a week prior to surgery
- If the patient has GI symptoms such as serious bloating or N/V, consider delaying the procedure
- If the patient has no GI symptoms but did not hold the GLP-1 agonist, then use "full stomach" precautions

However, critics of this guidance have noted:

- EGD studies that examined whether GLP-1 agonist use is associated with retained gastric contents have yielded mixed results
- The duration that GLP-1 agonist need to be held to reduce the risk of retained gastric contents is unclear
- The benefits of better glycemic control may be offsetting



Source: https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative

47

Periop Management of Diabetes Medications

Figure. Suggested Administration of Insulin and Other Diabete	es Medicat	ions on the M	orning of Surgery		
Patient due for elective surgery	Medication plan for morning of surgery				
No known type 1 diabetes and no similar clinical features	Hold	50% Dose	Continue normal therapy		
► Noninsulin therapies only					
Combination of insulin and noninsulin therapies • Long- and intermediate-acting insulin		•			
► Short- or rapid-acting insulin and noninsulin therapies					
Known type 1 diabetes or similar clinical features present ^a	Continue	basal insulin th	erapy		
Combination of short- or rapid-acting and intermediate-acting insulin • Short- or rapid-acting insulin	•				
► Intermediate-acting insulin		•			
Combination of short- or rapid-acting and long-acting insulin • Short- or rapid-acting insulin	•				
► Long-acting insulin (appropriate dose)			•		
► Long-acting insulin (inappropriately high dose)					
Indications for inappropriately high long-acting insulin dose: Frequent hypolycemia, especially at hight or early morning Steep overnight decline in blood glucose (>40 mg/dL) Patient requires bedtime snack to avoid hypoglycemia Long-acting insulin dose is >60% of total daily insulin dose		•			
Insulin pump therapy • Continued perioperative insulin pump use is not indicated	•		insulin pump and nous insulin infusion therapy		
► Continued perioperative insulin pump use is indicated					
Indications for continued perioperative use: Patient has good glucose control and is adept at pump usage Short surgery duration (<2 h) and quick recovery expected No hemodynamic compromise Pump infusion site is not close to surgical field			Reduce to 25% if basal rate is inappropriately high		

Source: Simha V, Shah P. Perioperative Glucose Control in Patients With Diabetes Undergoing Elective Surgery. JAMA. Jan 7 2019.

- The BRIDGE trial randomized 1884 patients with Afib on coumadin who were scheduled for an elective procedure to either bridging with LMWH (dalteparin) or placebo.
- ullet Patients had to have at least 1 of the CHADS $_2$ risk factors.
- The mean CHADS₂ score was 2.3



Source: Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. NEIM. 2015;373(9):823-833.

..

Bridging Anticoagulation


Table 3. Study Outcomes.							
Outcome	No Bridging (N=918)	Bridging (N = 895)	P Value				
	number of pati	ents (percent)					
Primary							
Arterial thromboembolism	4 (0.4)	3 (0.3)	0.01*, 0.73†				
Stroke	2 (0.2)	3 (0.3)					
Transient ischemic attack	2 (0.2)	0					
Systemic embolism	0	0					
Major bleeding	12 (1.3)	29 (3.2)	0.005†				
Secondary							
Death	5 (0.5)	4 (0.4)	0.88†				
Myocardial infarction	7 (0.8)	14 (1.6)	0.10†				
Deep-vein thrombosis	0	1 (0.1)	0.25†				
Pulmonary embolism	0	1 (0.1)	0.25†				
Minor bleeding	110 (12.0)	187 (20.9)	<0.001†				

^{*} P value for noninferiority.



[†] P value for superiority.

Bridging Anticoagulation with DOACS



Source: Douketis ID at al Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review. JAMA. 2024 Sep 10;332(10):825-834.

51

DOAC dose taken
 DOAC dose taken
 if hemostasis secured

衄

Perioperative Pulmonary Complications

Table 1. The Seven ARISCAT Risk Predictors, β Regression Coefficients, and Points Assigned*

	β Regression Coefficients	Score
Age (yr)		
≤50	0	0
51-80	0.331	3
>80	1.619	16
Preoperative Spo,		
≥96%	0	0
91-95%	0.802	8
≤90%	2.375	24
Respiratory infection in the	e last month	
No	0	0
Yes	1.698	17
Preoperative anemia (Hb s	≤10 a/dl)	
No	0	0
Yes	1.105	11
Surgical incision		
Peripheral	0	0
Upper abdominal	1.480	15
Intrathoracic	2.431	24
Duration of surgery (h)		
<2	0	0
2-3	1.593	16
>3	2.268	23
Emergency procedure		
No	0	0
Yes	0.768	8

- Tested on 5,859 patients in 63 centers
- Respiratory complications were defined as:
 - · Respiratory infection or failure
 - Bronchospasm
 - Atelectasis
 - · Pleural effusion
 - Pneumothorax
 - · Aspiration pneumonitis
- Score:
 - < 26 denotes a 3.4% risk
 - 26-45 denotes a 13.0% risk
 - >45 denotes a 38.0% risk



Perioperative Pulmonary Risk Reduction Strategies: Lung Expansion

- In patients at elevated risk, such as those undergoing abdominal surgery, a lung expansion maneuver is appropriate, and is more effective than no intervention
- Options include incentive spirometry, lung expansion exercises, and continuous positive airway pressure
- There is no compelling evidence favoring one lung expansion intervention over another
- CPAP may be appropriate in patients who are unable to undergo either incentive spirometry or lung expansion exercises. CPAP is advisable in OSA patients.



Source: Lawrence VA, et al. Strategies to reduce postoperative pulmonary complications after noncardiothoracic surgery: systematic review for the American College of Physicians. Annals of Internal Medicine. Apr 18 2006;144(8):596-608.


53

Perioperative Pulmonary Risk Reduction Strategies

- Smoking cessation
 - May help reduce the incidence of postop pulmonary complications
 - However, smoking cessation immediately (< 8 weeks) prior to surgery may increase the risk of postop pulmonary complications
- Anesthesia techniques need to be considered
 - Patients who had residual muscle blockade after receiving the long-acting neuromuscular-blocking agent pancuronium had an increased rate of postop pulmonary complications compared to patients without residual muscle blockade
 - Use of regional anesthesia, compared to general anesthesia, may also reduce the incidence of postop pulmonary complications




General versus Regional Anesthesia Complications Propensity Matched General Surgical Population (NSQIP) (n=328,540)



Source: Saied NN et al. Effect of anaesthesia type on postoperative mortality and morbidities: a matched analysis of the NSQIP database. Br J Anaesth. 2017 Jan;118(1):105-111.

55


General versus Regional Anesthesia Complications Propensity Matched COPD Patients (NSQIP) (n=5288)



Source: Hausman MS Jr at al. Regional versus general anesthesia in surgical patients with chronic obstructive pulmonary disease ... Anesth Analg. 2015 Jun;120(6):1405-12.

The Timing of Surgery for Hip Fracture Patients

- Retrospective cohort analysis of 42,230 hip fracture patients in Ontario
- Mean age around 80, around 70% female
- Primary outcome was 30-d mortality





Source: Pincus D, Ravi B, Wasserstein D, et al. Association Between Wait Time and 30-Day Mortality in Adults Undergoing Hip Fracture Surgery. JAMA. Nov 28 2017;318(20):1994-2003.

57

Periop Issues for OSA Patients

- Both respiratory and cardiovascular periop complications are more common in patients with untreated OSA than comparable patients without OSA
- Prescribing CPAP for patients with OSA perioperatively reduced the risk of cardiovascular but not pulmonary complications
- Neglecting to prescribe CPAP in patients on CPAP when postop in the hospital is an "unforced error"



Periop Issues for Obese Patients

- There are an increasing number of case reports of obese patients having postop rhabdomyolysis
- It is likely that the immobilization and weight on the gluteal muscle results in necrosis
- If an obese patient has postop AKI, consider rhabdomyolysis and check a CK
- Obese patients has restrictive lung physiology, and so consider CPAP in hypoxic obese patients postop



Source: Cote DR, Fuentes E, Elsayes AH, Ross JJ, Quraishi SA. A "crush" course on rhabdomyolysis: risk stratification and clinical management update for the perioperative clinician. J Anesth. 2020 Aug;34(4):585-598


- 5

Frailty

Fried Frailty Index:

- **1. Shrinking**: Unintentional weight loss ≥ 10 lbs
- **2. Physical endurance/energy**: During the last 4 weeks how often you rested in bed during day?
- **3.** Low physical activity: Low frequency of mildly energetic, moderately energetic and very energetic physical activity
- 4. Weakness: Based on poor handgrip strength
- **5. Slow walking speed**: Taking ≥ 6-7 sec to walk over 15 feet (depending on sex and height)









Figure. Odds Ratios (ORs) for 30-Day Mortality Among Patients Who Received Preoperative Medical Consultation vs Those Who Did Not (in Matched Subgroups) Did not | Received receive preoperative medical consultation preoperative medical OR (95% CI) consultation Entire matched cohort 1.19 (1.11-1.29) Year 2005-2010 1.12 (1.02-1.23) Year 2011-2017 Teaching hospital 1.20 (1.07-1.35) Nonteaching hospital 1.31 (1.19-1.45) Female 1.29 (1.15-1.46) Age 40-64 y 1.51 (1.23-1.86) Age ≥65 y 1.22 (1.13-1.32) Ischemic heart disease 1.03 (0.91-1.18) No ischemic heart disease 1.33 (1.22-1.46) Diabetes 1.17 (1.03-1.33) No diabetes 1.29 (1.18-1.41) 1.40 (1.01-1.94) 1.10 (0.98-1.25) 1.02 (0.76-1.38) RCRI = 1-2 RCRI≥3 Pulmonary disease Source: Varley PR. Buchanan D. No pulmonary disease 1.25 (1.15-1.36) Bilderback A, Wisniewski MK, Vascular procedure 1.34 (1.11-1.62) Johanning J. Nelson JB. Johnson JT. Abdominal/thoracic procedure 1.32 (1.19-1.46) Minnier T, Hall DE. Association of Orthopedic procedure 1.08 (0.92-1.27) Routine Preoperative Frailty Assessment With 1-Year Postoperative Mortality, JAMA Surg. No anesthesia consultation 1.31 (1.12-1.53) 2023 May 1;158(5):475-483. OR (95% CI) 衄 63 RCRI indicates Revised Cardiac Risk Index.

Clinical Case

- 76-year-old male with severe COPD, on 3 L of home O₂ and chronic prednisone 7.5 mg daily, DMII on metformin, dyspnea with minimal exertion.
- No history of MI or CHF. His EKG is essentially normal.
- He has metastatic colon cancer, with a single metastasis to the brain causing left arm weakness
- You are seeing him in consultation prior to neurosurgery scheduled 48 h from now to resect the metastasis
- He underwent successful resection of a colon mass 3 years ago





Clinical Case

- What actually happened:
 - The neurosurgeon cancelled the case
 - The patient was scheduled for brain XRT instead
 - Surgery remained on the table as an option
- If the patent undergoes surgery, consider cort stim versus stress dose steroids



Summary/Take Home Points

- Use one of the on-line risk assessment tools to determine the MACE risk of your patients
- Consider the role for the various perioperative risk reduction interventions
 - Medical: beta blockers, statins
- Have a plan for perioperative management of different medications, such as ACEI/ARBs, ASA, and diabetes medications
- Perioperative risk is more than just cardiovascular risk
- Communicate with the surgeon and anesthesiologist

